Independent newsroom

Tuesday, November 10, 2026

The File

Every claim traces to a primary source. Uncertainty is labeled. Corrections are public.

Health · Tuesday, November 10, 2026

FDA requires GLP-1 labels to warn of rare vision loss

The File desk · Nov. 10, 2026, 6:47 a.m. ET

Confirmed1 primary sourcesAdded 6:47 a.m. ET, Nov. 10

Status

Confirmed as the FDA's action. The Drug Safety Communication dated November 9, 2026, says the agency is requiring GLP-1 RA labels to add a Warnings and Precautions statement about a potential increased risk of NAION. The risk finding and the advice to patients and clinicians are the FDA's.
The Food and Drug Administration said on November 9, 2026, that makers of a widely used class of diabetes and weight-loss drugs must add a warning about a rare eye condition that can cause sudden vision loss in one eye.1 Adding the warning is not a recall, and the drugs stay on the market.1
The agency calls the drugs glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. They mimic a hormone the intestine releases, one that lowers blood sugar after a meal and acts on parts of the brain that control appetite. The FDA says the drugs are widely used for type 2 diabetes or to reduce excess body weight.1
The eye condition is non-arteritic anterior ischemic optic neuropathy, or NAION. In the agency's words, NAION is "a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss." The FDA is requiring the companies that hold the approvals to add that risk to the Warnings and Precautions section of the label, the part where a label states serious risks a prescriber should know.1
In the agency's review of its clinical trials, it counted 6.4 NAION cases per 100,000 person-years among people on these drugs. Among people given a placebo or a different kind of diabetes drug, it counted 3.8.1
Patients should contact their health care professional right away if they have sudden, painless vision loss in one eye, blurred or missing portions of vision, distortion of colors, or reduced central sharpness. The FDA says those symptoms may be noticed upon waking. If a patient has already had a NAION event, "they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it."1
Why it matters (Estimate). Estimate. People who take these drugs for type 2 diabetes or to lose weight are the ones the warning is for. The FDA's instruction is specific: call a health care professional right away about sudden painless vision loss in one eye, and if NAION has already happened, talk with that professional about whether to continue. The drugs are not being pulled off the market.
Clinicians are told to have patients report sudden vision changes immediately and to refer a suspected case to an ophthalmologist. The agency also tells them to consider stopping the drug unless the benefits clearly outweigh the risk.1
How we know

Notes

  1. 1.FDA Drug Safety Communication, November 9, 2026. "The U.S. Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss." "The agency is requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling." GLP-1 RAs "mimic the effects of a natural hormone called glucagon-like peptide-1 (GLP-1) that the intestine releases." They are "widely used to treat people with type 2 diabetes or to reduce excess body weight." Symptoms include "sudden, painless vision loss in one eye that patients may notice upon waking; blurred or missing portions of vision (visual defects such as blind spots or tunnel vision); distortion of colors; and reduced central sharpness." "Patients should contact their health care professional right away if they have any of these symptoms." "If a patient has had a NAION event, they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it." Clinicians: "Instruct patients to immediately report sudden onset of acute, painless, decreased vision" and "promptly refer the patient to an ophthalmologist." "Consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk." A meta-analysis of 126 randomized trials found 6.4 NAION cases per 100,000 person-years on GLP-1 RAs and 3.8 on a comparator. The product table names Byetta (exenatide, 2005; the application was withdrawn and only generic exenatide is marketed), Victoza (liraglutide, 2010), Trulicity (dulaglutide, 2014), Saxenda (liraglutide, 2014), Xultophy (liraglutide and insulin degludec, 2016), Soliqua (lixisenatide and insulin glargine, 2016), Ozempic (semaglutide, 2017), Rybelsus (semaglutide, 2019), Wegovy (semaglutide, 2021), Mounjaro (tirzepatide, 2022), Zepbound (tirzepatide, 2023), and Foundayo (orforglipron, 2026). Retrieved 6:24 a.m. ET, Nov. 10. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential

What is still unknown or disputed

  • Whether any company has already printed the new warning. The communication requires the change and does not say the wording is already on the box.
  • How many people take the drugs. The page says they are widely used and does not print a patient total.

Primary sources

Every claim in this story is drawn from the documents below. If a fetch failed, that is recorded on the card.

  1. Source 1

    FDA Requires Safety Labeling Changes for GLP-1 RAs

    U.S. Food and Drug Administration · November 9, 2026

    The FDA is requiring GLP-1 RA labels to add a Warnings and Precautions statement on a potential increased risk of NAION, a rare condition that can cause acute, painless, decreased vision in one eye, including permanent vision loss. Dated November 9, 2026.

    https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential